This multi-center, non-interventional study will evaluate the pattern of usage in clinical practice, efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Patients initiated on treatment with RoActemra/Actemra according to the licensed Canadian product monograph recommendations will be followed for 12 months from the start of treatment.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01613378?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
